While deficiencies in HR and MMR pathways have both been demonstrated to lead to improved response with cancer immunotherapy, deficiencies in several other key DNA repair pathways, including TLS, FA, R-loop processing pathways, and ATM mutations in tumors, have all been under-studied in the context of cancer immunotherapy response. The gene discussed is MRC1; the disease is cancer.